Viewing nowPioglitazone 15 mg
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 200702710 · Approved 2007.03.05 · Insurance code 657303580
Improvement of glycemic control in type 2 diabetes mellitus
This medication assists in blood sugar control for type 2 diabetes patients by supplementing dietary and exercise therapies. It can be used alone or in combination with sulfonylureas, metformin, or insulin if there is no effect after using other oral hypoglycemic agents. Additionally, diabetes patients should receive nutritional counseling, weight loss, and regular exercise therapy, as these efforts are crucial not only for initial treatment but also for maintaining the efficacy of the medication. This medication is used to improve blood sugar control in type 2 diabetes patients.
This medicine is administered orally once daily, regardless of meals. Management of diabetes should be individualized for each patient. Ideally, response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. In clinical practice, this medicine should be administered for an adequate period to evaluate changes in glycated hemoglobin (at least 3 months), provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If an adequate effect is not achieved with the initial dose of this medicine, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylurea: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dosage and administration schedule. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dosage and administration schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin; the dose is 15 mg once daily. The current insulin dose may be continued when combination therapy with this medicine is initiated. However, if a patient receiving this medicine in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to the degree of glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal insufficiency (refer to the Precautions section, Patients with Renal Impairment). Do not initiate treatment with this medicine if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (refer to Adverse Reactions and Precautions, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before starting treatment with this medicine and periodically thereafter. There are no data on the use of this medicine in combination therapy with another thiazolidinedione.
Use is not recommended in children under 18 years of age because there is no experience with its use in this age group.
This medication helps control blood sugar in type 2 diabetes patients. However, it should not be taken by patients with heart failure or those with a history of heart failure, as it may exacerbate the condition. Furthermore, this medication may cause fluid retention, leading to swelling or weight gain; if symptoms of swelling occur, consult a physician immediately. Patients with a history of heart disease, hypertension, or myocardial infarction should be particularly cautious, and if symptoms such as shortness of breath, swelling, or rapid weight gain appear during treatment, they should inform healthcare personnel immediately. This medication should not be administered to patients with bladder cancer or a history of bladder cancer, and immediate consultation with a physician is necessary if symptoms like urination difficulties or hematuria occur. It is also advised not to administer this medication to patients with severely impaired liver or kidney function, and if symptoms of liver dysfunction arise, testing should be conducted, and the medication should be discontinued if necessary. The risk of hypoglycemia may increase when used with other hypoglycemic agents; therefore, caution should be exercised regarding hypoglycemia symptoms, and adjustments to the dosages of other medications may be necessary. For premenopausal women, this medication may stimulate ovulation, thereby increasing the risk of pregnancy; appropriate contraception is recommended. Women who are pregnant or may become pregnant should avoid this medication, and those who are breastfeeding should consult with a physician. Elderly or malnourished patients may be at higher risk for hypoglycemia or side effects, so caution is needed. During treatment, regular monitoring of blood sugar and liver function is necessary, and any changes in physical condition should be reported to healthcare personnel promptly. This medication is taken once a day, and if a dose is missed, do not double the dose the next day. Finally, it is not used in children as safety and efficacy have not been established.
Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, edema, headache, sinusitis, myalgia, pharyngitis, abdominal bloating, weight gain, hypoglycemia, upper respiratory infection, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular causes, hospitalization due to worsening congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular abnormalities, liver failure, diabetic macular edema accompanied by visual reduction, liver damage, macular edema, fractures, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, cough, itching, chest discomfort, tremors, chills, gastrointestinal disorders, abdominal pain, epigastric discomfort, numbness, muscle rigidity, head discomfort, elevated liver enzymes, worsening liver disease, hives, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simplex herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure
Not everyone experiences these, and they can vary from person to person.
Store this medication in a container that can block light and air, and ensure it is protected from moisture. The storage temperature should be between 15 to 30 degrees Celsius, with around 25 degrees being ideal.
White to off-white, round, convex tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.